These data corroborated the findings from non‐diabetic tumor models with glucagon treatment, which further raises the possibility that endogenous glucagon derived from HDF models may contribute to sensitizing 5‐FU treatment on CRCs. This evidence concerns the gene GCG and neoplasm.